Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moshen granule is a Traditional Chinese Medicine (TCM) formulation developed by the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. It is specifically designed for the treatment of primary membranous nephropathy (PMN). The formulation is based on the TCM therapeutic principles of invigorating the spleen, benefiting the kidney, dispelling wind, and dredging collaterals. In clinical studies, it is evaluated for its efficacy in reducing proteinuria and improving renal function in patients with PMN, either as a monotherapy or in combination with standard treatments like angiotensin receptor blockers or immunosuppressants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Moshen granule.